Ozempic vs Wegovy: Key Differences Explained
Ozempic and Wegovy are both semaglutide medications but differ primarily in their FDA-approved indication: Ozempic treats type 2 diabetes while Wegovy is approved for chronic weight management in obese or overweight patients. Wegovy uses higher doses and is marketed specifically for weight loss, whereas Ozempic's weight loss is a secondary benefit.
Ozempic
GLP-1 receptor agonist approved by FDA for type 2 diabetes blood sugar control
Type 2 diabetic patients seeking improved glucose control with the added benefit of weight loss
Wegovy
GLP-1 receptor agonist approved by FDA specifically for chronic weight management
Obese or overweight individuals (BMI ≥30 or ≥27 with weight-related comorbidities) whose primary goal is significant weight loss
Quick Answer
AI SummaryOzempic and Wegovy are both semaglutide medications but differ primarily in their FDA-approved indication: Ozempic treats type 2 diabetes while Wegovy is approved for chronic weight management in obese or overweight patients. Wegovy uses higher doses and is marketed specifically for weight loss, whereas Ozempic's weight loss is a secondary benefit.
Our Verdict
AI-assistedBoth medications contain the same active ingredient (semaglutide) and are highly effective, but serve different primary purposes. Ozempic is the better choice for type 2 diabetes patients seeking diabetes control with weight loss as a bonus, while Wegovy is superior for individuals whose primary goal is significant weight management. Choice should align with medical needs, insurance coverage, and physician guidance.
Was this verdict helpful?
Choose Ozempic if
Best pickType 2 diabetic patients seeking improved glucose control with the added benefit of weight loss
Choose Wegovy if
Obese or overweight individuals (BMI ≥30 or ≥27 with weight-related comorbidities) whose primary goal is significant weight loss
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Primary FDA Approval:Type 2 Diabetes vs Chronic Weight Management
- Maximum Approved Dose:✓ Wegovy wins(2.4 mg weekly vs 2.0 mg weekly)
- Average Weight Loss:✓ Wegovy wins(15-22% body weight vs 5-7% body weight)
Key Facts & Figures
30 numeric metrics compared
| Metric | Ozempic | Wegovy | Ratio |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300 | |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation) | |
| FDA Approval Year | 2017 | 2021 | |
| Number of Dose Strengths Available(strengths) | 4 | 5 | |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22% | |
| FDA Approval Year(year) | 2017 (diabetes) | 2021 (weight management) | |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% | |
| Injection Frequency(times per week) | 1 | 1 | |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | $1,350-1,600 | |
| Time to Maintenance Dose(weeks) | 12 | 16 | |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | 0.5-1.0 | |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — | — |
| Injection Schedule(per week) | Once weekly | — | — |
| Average Retail Price(USD/month) | $900-1,300 | — | — |
| Number of Dose Strengths Available(options) | 3 | — | — |
| Time on Market(years) | 9 years | — | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | 2.4mg weekly | |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction | |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | $1,349-$1,550 | |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | 25% (at 2.4mg dose) | |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | 35-45% (weight loss coverage limited) | |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg | |
| Average Weight Loss (Clinical Trial)(% body weight) | 5-7% (diabetes indication) | 15% (weight management trials) | |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks | |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | $1,300-1,500 | |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | 10-20% (excluded as cosmetic) | |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — | — |
Sourced from publicly available data ·
Key Differences
8 attributes compared head-to-head
- Type 2 DiabetesPrimary FDA ApprovalChronic Weight Management
- 2.0 mg weeklyMaximum Approved Dose2.4 mg weekly(winner)
- 5-7% body weightAverage Weight Loss15-22% body weight(winner)
- Better for diabetes patients(winner)Insurance CoverageLimited; often out-of-pocket
- $900-1,200(winner)Cost Per Month (2026)$1,350-1,600
- Common but not approvedOff-Label Weight Loss UseOfficially approved(winner)
- Diabetic patientsTarget Patient PopulationObese/overweight individuals
- 12-week titration period(winner)Dosing Schedule16-week titration period
- Primary FDA Approval
Ozempic
Type 2 Diabetes
Wegovy
Chronic Weight Management
- Maximum Approved Dose
Ozempic
2.0 mg weekly
Wegovy
2.4 mg weekly(winner)
- Average Weight Loss
Ozempic
5-7% body weight
Wegovy
15-22% body weight(winner)
- Insurance Coverage
Ozempic
Better for diabetes patients(winner)
Wegovy
Limited; often out-of-pocket
- Cost Per Month (2026)
Ozempic
$900-1,200(winner)
Wegovy
$1,350-1,600
- Off-Label Weight Loss Use
Ozempic
Common but not approved
Wegovy
Officially approved(winner)
- Target Patient Population
Ozempic
Diabetic patients
Wegovy
Obese/overweight individuals
- Dosing Schedule
Ozempic
12-week titration period(winner)
Wegovy
16-week titration period
Full Comparison
| Attribute | Ozempic | Wegovy |
|---|---|---|
| Average Weight Loss(%) | 8-12% | 15-22%(winner) |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22%(winner) |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction(winner) |
Show 1 more attributeAverage Weight Loss (Clinical Trial)(% body weight) 5-7% (diabetes indication) 15% (weight management trials) | ||
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300(winner) |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200(winner) | $1,350-1,600 |
| Average Retail Price(USD/month) | $900-1,300 | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100(winner) | $1,349-$1,550 |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200(winner) | $1,300-1,500 |
| Active Ingredient | Semaglutide | Semaglutide |
| Active Pharmaceutical Ingredient | Semaglutide (recombinant human GLP-1 analog) | Semaglutide (recombinant human GLP-1 analog) |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation)(winner) |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly(winner) | 2.4mg weekly |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg(winner) |
| FDA Approval Year | 2017(winner) | 2021 |
| FDA Approval Year(year) | 2017 (diabetes)(winner) | 2021 (weight management) |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — |
| Primary Indication | Type 2 Diabetes | Weight Loss & Obesity |
| Cardiovascular Benefits | Proven in diabetic patients | Proven in overweight/obese patients |
| Typical Insurance Coverage | Widely covered for diabetes | Limited coverage for weight loss |
| Number of Dose Strengths Available(strengths) | 4 | 5(winner) |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | Semaglutide (GLP-1 receptor agonist) |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose)(winner) | 25% (at 2.4mg dose) |
| Injection Frequency(times per week) | 1 | 1 |
| Injection Schedule(per week) | Once weekly | — |
| Time to Maintenance Dose(weeks) | 12(winner) | 16 |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0(winner) | 0.5-1.0 |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | — |
| Number of Dose Strengths Available(options) | 3 | — |
| Time on Market(years) | 9 years | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication)(winner) | 35-45% (weight loss coverage limited) |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks(winner) |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label)(winner) | 10-20% (excluded as cosmetic) |
| Injection Frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — |
OzempicWegovyShow 1 more attribute
Pros & Cons
10 pros·5 cons across both
Ozempic
Pros
- Better insurance coverage for diabetic patients
- Lower out-of-pocket costs in most cases
- Improves HbA1c levels and blood glucose control
- Reduces cardiovascular disease risk in type 2 diabetics
- Well-established safety profile in diabetes treatment
Cons
- Lower average weight loss compared to Wegovy
- Gastrointestinal side effects (nausea, vomiting) in 25-40% of users
Wegovy
Pros
- FDA-approved specifically for weight loss and weight management
- Significantly higher average weight loss (15-22% of body weight)
- Improves cardiovascular outcomes in overweight/obese patients
- Higher maximum approved dose for enhanced efficacy
- Reduces progression to type 2 diabetes in high-risk individuals
Cons
- Expensive with limited insurance coverage for weight loss indication
- Gastrointestinal side effects (nausea, vomiting) in 25-40% of users
- Longer titration period (16 weeks) before reaching maintenance dose
Frequently Asked Questions
5 questions
While Ozempic can produce weight loss as a side effect, it is not FDA-approved for weight loss in non-diabetic patients. Using it off-label for weight loss is common but should only be done under physician supervision. Wegovy is the FDA-approved option specifically designed for chronic weight management in non-diabetic individuals.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
Related Comparisons
12 more to explore
Ozempic vs Wegovy
healthOzempic vs Mounjaro
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
healthContact Lenses vs Glasses
health
Related Articles
1 article
Explore More
Related comparisons and categories